MRVT Stock Overview
Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Miravant Medical Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 0% |
| 3 Year Change | -99.97% |
| 5 Year Change | 0% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| MRVT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | -3.1% |
| 1Y | 0% | 11.3% | 20.9% |
Return vs Industry: MRVT underperformed the US Pharmaceuticals industry which returned 11.5% over the past year.
Return vs Market: MRVT underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| MRVT volatility | |
|---|---|
| MRVT Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRVT has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MRVT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | n/a | n/a |
Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors.
Miravant Medical Technologies Inc. Fundamentals Summary
| MRVT fundamental statistics | |
|---|---|
| Market cap | US$37.00 |
| Earnings (TTM) | -US$15.34m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs MRVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRVT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$15.34m |
| Earnings | -US$15.34m |
Last Reported Earnings
Sep 30, 2005
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did MRVT perform over the long term?
See historical performance and comparison